Latest Content

CMS is withholding $9.8 billion in Texas Medicaid hospital funding tied to CHIRP, costing hospitals $27 million a day in a tax dispute.

Yet Khor discusses why a 20% CT emphysema threshold, not spirometry alone, best identifies CPFE and predicts outcomes in fibrotic ILD.

A national study found comorbidities may drive worse long-term survival among patients with MASH awaiting or undergoing liver transplant.

Switching Medicare Advantage (MA) plans is increasingly common among MA enrollees, especially those dually eligible for Medicaid, but this varies by demographic group.

The One Big Beautiful Bill Act restructures Medicaid coverage in ways that have a direct impact on oncology programs. This commentary presents a three-domain operational framework intended for cancer program administrators.

Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status and eosinophil levels.

The combination therapy met the primary OS end point vs durvalumab alone as first-line ES-SCLC maintenance therapy in the phase 3 DeLLphi-305 trial.

FDA approved zilganersen (ZANVASTRO), the first disease-modifying treatment for Alexander disease, based on pivotal trial data.

Despite positive data, the study authors call for prospective validation before PRO burden is incorporated into broader risk-stratification approaches.